CB stimulates the sensitivity of NPC cells to CP therapy by activating FOXO1 and subsequently inhibiting MYH9, which leads to a reduction in cancer rigidity and inhibition of EMT (E-cadherin upregulation, and N-cadherin downregulation) [217]. The gene discussed is CDH2; the disease is cancer.